HIG Capital, a private equity firm, completed the acquisition of Celerion Holdings, a provider of outsourced clinical research services to the pharmaceutical industry. Financial terms were not disclosed. “We are excited to enter into this new chapter of growth with HIG. Celerion is one of the most experienced and successful CROs globally, with expertise in early stage drug development solutions that has resulted in strong growth since the Company’s inception. We look forward to partnering with HIG, who brings significant experience and resources in the pharmaceutical sector, and continuing to provide industry leading customer service," Susan Thornton, Celerion CEO.